Kistler Tiffany Companies LLC cut its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 13.3% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 6,961 shares of the biopharmaceutical company’s stock after selling 1,066 shares during the period. Kistler Tiffany Companies LLC’s holdings in Gilead Sciences were worth $435,000 as of its most recent SEC filing.
A number of other large investors have also modified their holdings of GILD. Waldron Private Wealth LLC boosted its holdings in Gilead Sciences by 3.8% in the third quarter. Waldron Private Wealth LLC now owns 4,372 shares of the biopharmaceutical company’s stock valued at $337,000 after purchasing an additional 162 shares in the last quarter. Cornerstone Advisors Inc. boosted its holdings in Gilead Sciences by 6.1% in the third quarter. Cornerstone Advisors Inc. now owns 3,120 shares of the biopharmaceutical company’s stock valued at $241,000 after purchasing an additional 178 shares in the last quarter. North Star Investment Management Corp. boosted its holdings in Gilead Sciences by 11.5% in the fourth quarter. North Star Investment Management Corp. now owns 2,199 shares of the biopharmaceutical company’s stock valued at $138,000 after purchasing an additional 226 shares in the last quarter. Plimoth Trust Co. LLC boosted its holdings in Gilead Sciences by 0.8% in the third quarter. Plimoth Trust Co. LLC now owns 43,856 shares of the biopharmaceutical company’s stock valued at $3,386,000 after purchasing an additional 365 shares in the last quarter. Finally, Park National Corp OH boosted its holdings in Gilead Sciences by 7.9% in the fourth quarter. Park National Corp OH now owns 7,388 shares of the biopharmaceutical company’s stock valued at $463,000 after purchasing an additional 541 shares in the last quarter. Institutional investors own 78.01% of the company’s stock.
In other news, Director John C. Martin sold 50,000 shares of the company’s stock in a transaction that occurred on Monday, December 3rd. The stock was sold at an average price of $71.20, for a total transaction of $3,560,000.00. Following the completion of the sale, the director now owns 2,877,762 shares in the company, valued at $204,896,654.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 1.16% of the stock is owned by corporate insiders.
Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Thursday, October 25th. The biopharmaceutical company reported $1.84 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.63 by $0.21. Gilead Sciences had a return on equity of 39.32% and a net margin of 7.12%. The business had revenue of $5.60 billion during the quarter, compared to the consensus estimate of $5.44 billion. During the same period in the prior year, the company earned $2.27 earnings per share. Research analysts predict that Gilead Sciences, Inc. will post 6.44 EPS for the current fiscal year.
The business also recently declared a quarterly dividend, which was paid on Friday, December 28th. Stockholders of record on Friday, December 14th were paid a dividend of $0.57 per share. This represents a $2.28 annualized dividend and a dividend yield of 3.38%. The ex-dividend date of this dividend was Thursday, December 13th. Gilead Sciences’s dividend payout ratio (DPR) is presently 26.64%.
A number of brokerages recently issued reports on GILD. ValuEngine raised Gilead Sciences from a “sell” rating to a “hold” rating in a report on Saturday, December 1st. Mizuho set a $94.00 price target on Gilead Sciences and gave the company a “buy” rating in a report on Thursday, November 1st. Zacks Investment Research downgraded Gilead Sciences from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 25th. CIBC raised Gilead Sciences from a “market perform” rating to an “outperform” rating and set a $85.00 price target for the company in a report on Thursday, January 3rd. Finally, Raymond James lowered their price target on Gilead Sciences from $97.00 to $94.00 and set a “strong-buy” rating for the company in a report on Friday, October 26th. Ten investment analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $88.39.
TRADEMARK VIOLATION NOTICE: This article was originally published by Community Financial News and is owned by of Community Financial News. If you are viewing this article on another domain, it was copied illegally and republished in violation of international trademark & copyright legislation. The original version of this article can be accessed at https://www.com-unik.info/2019/01/14/kistler-tiffany-companies-llc-sells-1066-shares-of-gilead-sciences-inc-gild.html.
About Gilead Sciences
Gilead Sciences, Inc discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.
Featured Article: How To Calculate Debt-to-Equity Ratio
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.